WEIGHT LOSS TREATMENTS

A day after the AAP claimed that Delhi Chief Minister Arvind Kejriwal had lost 8.5 kg in prison, Tihar jail sources on Monday said he had only lost 2 kg. The jail authorities also mentioned that he was being regularly monitored by a medical board fr...

Statistics show low treatment target compliance among Indian diabetes patients, increasing heart disease risks. Timely screening and weight management are crucial for better health outcomes. Learn more about the importance of integrated management.

A recent study conducted by researchers at Massachusetts Eye and Ear hospital has found a significant link between popular weight loss drugs containing semaglutide and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a ...

Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a...

Proactively collaborating with healthcare professionals for personalized strategies enhances diabetes management, leading to improved overall well-being and better health outcomes.

India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find...

People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage...

Novo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The Bengaluru-based Global Business Services unit collaborated on clinical trials and biostatistics. Despite glob...

Diabetes cases in India are rising, with 101 million individuals affected according to ICMR- INDIAB data. The International Diabetes Federation projects a 46% increase in global diabetes cases by 2045.

​The mainstays of cancer treatment remain surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy and hormone therapy. But there are other treatments and strategies - "adjunct" or supportive cancer care - that can have a powerful i...

Managing type 2 diabetes involves crucial lifestyle changes for blood sugar control, mental health support, weight management, nutrition therapy, stress management, physical activity, and glucose regulation.

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife fo...

"Nothing comes without a downside. These molecules do produce significant nausea and vomiting in some people — to the extent that they have to discontinue the medication. Some may develop diarrhoea, some may have severe constipation. Others may not ...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overwe...

Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.

Zeeshan Siddique, former Mumbai Youth Congress president, claimed he was told to lose weight before meeting Rahul Gandhi during the 'Bharat Jodo Yatra' in Maharashtra. He criticized the mistreatment of minority leaders within Congress. Siddique resi...

Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla...

According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five years, the market has grown at 32% CAGR to 474 crore in January 2024.

​Despite the significance of cachexia for cancer patients, there has been very little progress in treating the condition.